Dr. Cha is an accomplished physician-scientist with extensive experience in biotech research and drug development, both early and late stage, with comprehensive involvement in various oncologic indications involving diverse therapeutic approaches.
Prior to joining Samumed, Dr. Cha served as a Global Clinical Leader at Pfizer in several early oncology development programs in hematological malignancies, including Acute Myeloid Leukemia and Non-Hodgkin’s Lymphoma indications, and various solid tumor programs, including Prostate Cancer, Breast Cancer, Renal Cell Carcinoma, and Lung Cancer. Previously, he led the Metastatic Breast Cancer Franchise at Puma Biotechnology, developing neratinib in metastatic HER2+ Breast Cancer indication. Earlier in his career at Amgen, Dr. Cha was part of the Global NDA filing for romiplostim (Nplate®) and blinatumomab (BLINCYTO®). Dr. Cha was instrumental in implementation and execution of several post-marketing commitments, including REMS (Risk Evaluation and Mitigation Strategy) in the U.S. and several safety post-marketing registries and studies in the U.S., Canada, and EU.
Dr. Cha completed both his Hematology Fellowship training and Bone Marrow Transplant Fellowship training at Stanford University, received his medical degree from Tufts University School of Medicine, and received his B.S. in Biochemistry/Cell Biology from University of California, San Diego.